Thomas Caligiuri, MD
Nephrology · Fort Worth, TXNPI 1407318470
Payments from drug & device makers
Across 130 payments — averaging $33.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$841
- Otsuka America Pharmaceutical, Inc.$427
- Travere Therapeutics, Inc.$425
- Medtronic$287
- Mallinckrodt Hospital Products Inc.$276
- GSK$259
- plus $2K from 21 others
What the payments were for
- Food & beverage$4,12595%
- Education$2175%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 20 | $841 |
| Otsuka America Pharmaceutical, Inc. | 11 | $427 |
| Travere Therapeutics, Inc. | 10 | $425 |
| Medtronic | 3 | $287 |
| Mallinckrodt Hospital Products Inc. | 13 | $276 |
| GSK | 5 | $259 |
| Fresenius USA Marketing, Inc. | 12 | $250 |
| Daiichi Sankyo Inc. | 11 | $244 |
| Nxstage Medical, Inc. | 5 | $240 |
| Calliditas Therapeutics US Inc. | 7 | $227 |
| Penumbra, Inc. | 1 | $137 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $107 |
| Novartis | 4 | $98 |
| OPKO Pharmaceuticals, LLC | 6 | $97 |
| Bayer | 4 | $71 |
| Aurinia Pharma U.S., Inc. | 3 | $67 |
| Amgen | 2 | $47 |
| Vifor Pharma, Inc. | 2 | $46 |
| Mozarc Medical US LLC | 2 | $32 |
| Sanofi | 1 | $30 |
| Tactile Systems Technology Inc | 1 | $27 |
| Ardelyx, Inc. | 1 | $26 |
| Akebia Therapeutics Inc | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
| Merck | 1 | $14 |
| Lilly USA, LLC | 1 | $13 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LOKELMA$255
- JYNARQUE$227
- NXSTAGE SYSTEM ONE$150
- NXSTAGE PUREFLOW SOLUTION$150
- Penumbra System$137
- ELLIPSYS VASCULAR ACCESS SYSTEM$130
- IN.PACT AV$126
- INJECTAFER$125
- TARPEYO$125
- FARXIGA$125
How this compares
$4,342 in reported general payments places this provider in the 65th percentile of 1,070 nephrology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nifedipine ErNifedipine | 31 | $768 |
| Chlorthalidone | 17 | $351 |
| Losartan Potassium | 31 | $167 |
| Carvedilol | 20 | $155 |
| Spironolactone | 29 | $121 |
| Lisinopril | 19 | $111 |
| Amlodipine Besylate | 17 | $82 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Fort Worth
- Bernard FischbachFort Worth$870K
- Saravanan BalamuthusamyFort Worth$707K
- Pablo PergolaSan Antonio$14.2M
- German HernandezEl Paso$9.7M
- Sreedhar MandayamHouston$7M
- Tahira AlvesSan Antonio$6.1M
- Carl DukesSan Antonio$5.9M
- Chinonye Ogbonnaya-OdorSan Antonio$4.6M
- Marializa BernardoHouston$4.2M
- Judith BettsAustin$3.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.